American Association for Cancer Research

SHERPA: Unknown

People

  1. Hudis
    Hudis
  2. Patil
    Patil
  3. Norton
    Norton
  4. Traina
    Traina
  5. Dang
    Dang
  6. Dickler
    Dickler
  7. Modi
    Modi
  8. D'Andrea-Carlino
    D'Andrea-Carlino
  9. Lake
    Lake
  10. Mcarthur
    Mcarthur

Groups

  1. Breast Medicine Service (140)
  2. Department of Medicine (140)
  3. Solid Tumor Oncology Division (140)
  4. Survivorship Research (140)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (55)
  6. Epidemiology and Biostatistics (55)
  7. Biostatistics Service (50)
  8. GSK Faculty (38)
  9. Population Sciences Research Program (36)
  10. Department of Pathology and Laboratory Medicine (30)
Search Within
  1. "Clifford Hudis"
Formats
  1. Meeting Abstract (107)
  2. Journal Article (33)
Groups
  1. Breast Medicine Service (140)
  2. Department of Medicine (140)
  3. Solid Tumor Oncology Division (140)
  4. Survivorship Research (140)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (55)
  6. Epidemiology and Biostatistics (55)

More Groups

People
  1. Clifford Hudis (140)
  2. Larry Norton (48)
  3. Sujata Patil (42)
  4. Tiffany Traina (28)
  5. Chau Dang (27)
  6. Maura Dickler (27)

More People

Years
  1. 2021 (2)
  2. 2020 (1)
  3. 2018 (5)
  4. 2017 (6)
  5. 2016 (16)
  6. 2015 (19)

More Years

Publications
  1. Cancer Research (108)
  2. Clinical Cancer Research (32)

Results (140)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)
    Meeting Abstract

    Ma, C. X.; Suman, V.; Leitch, A. M.; Sanati, S.; Vij, K.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O.; Guenther, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)
    Meeting Abstract

    Ellis, M. J.; Suman, V.; Leitch, A. M.; Sanati, S.; Vij, K.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O.; Guenther, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • First-in-human trial of epichaperome-targeted PET in patients with cancer
    Journal Article

    Dunphy, M. P. S.; Pressl, C.; Pillarsetty, N.; Grkovski, M.; Modi, S.; Jhaveri, K.; Norton, L.; Beattie, B. J.; Zanzonico, P. B.; Zatorska, D.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Integrated analysis of RNA and DNA from the phase III trial CALGB 40601 identifies predictors of response to trastuzumab-based neoadjuvant chemotherapy in HER2-positive breast cancer
    Journal Article

    Tanioka, M.; Fan, C.; Parker, J. S.; Hoadley, K. A.; Hu, Z.; Li, Y.; Hyslop, T. M.; Pitcher, B. N.; Soloway, M. G.; Spears, P. A.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)
    Meeting Abstract

    Rugo, H. S.; Barry, W. T.; Moreno-Aspitia, A.; Lyss, A.; Huebner, L.; Mayer, E. L.; Naughton, M.; Layman, R. M.; Carey, L. A.; Somer, R. A.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer (MBC) patients predict poor clinical outcomes: CALGB 40502 (Alliance)/NCCTG N063H study
    Meeting Abstract

    Magbanua, M. J.; Hendrix, L.; Hyslop, T.; Barry, W. T.; Winer, E. P.; Hudis, C.; Toppmeyer, D.; Burnstein, H.; Qadir, M.; Ma, C.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Molecular subtyping of male breast cancer by the International Male Breast Cancer Program (IMBC): EORTC 10085/TBCRC 0-29/BIG 2-07/NABCG/BOOG 2009-04
    Meeting Abstract

    Martens, J. W. M.; Sieuwerts, A.; Ponchet, C.; Smid, M.; de Weerd, V.; Slaets, L.; Piper, T.; van Deurzen, C. H. M.; Schroder, C. P.; Stangle, C.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Molecular determinants of post-mastectomy breast cancer recurrence
    Meeting Abstract

    Keene, K. S.; King, T.; Hwang, E. S.; Peng, B.; McGuire, K.; Tapia, C.; Zhang, H.; Bae, S.; Nakhlis, F.; Klauber-Demore, N.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(-) metastatic breast cancer
    Journal Article

    Dickler, M. N.; Tolaney, S. M.; Rugo, H. S.; Cortés, J.; Diéras, V.; Patt, D.; Wildiers, H.; Hudis, C. A.; O'Shaughnessy, J.; Zamora, E.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Breast carcinoma with 21-gene recurrence score lower than 18: Rate of distant metastases in a large series with clinical follow-up
    Meeting Abstract

    Wen, H. Y.; Krystel-Whittemore, M.; Patil, S.; Pareja, F.; Bowser, Z. L.; Dickler, M.; Norton, L.; Morrow, M.; Hudis, C.; Brogi, E.
    Cancer Research (2017)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: